MAT 9001

Drug Profile

MAT 9001

Alternative Names: MAT-9001

Latest Information Update: 28 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Matinas BioPharma
  • Class Antihyperlipidaemics; Omega 3 fatty acids
  • Mechanism of Action Triglyceride modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Hypertriglyceridaemia
  • Preclinical Dyslipidaemias

Most Recent Events

  • 12 Sep 2017 Matinas BioPharma completes a phase I trial for Hypertriglyceridaemia in Canada (PO)
  • 20 Aug 2015 MAT 9001 is available for licensing as of 18 Aug 2015.
  • 15 Jun 2015 Additional pharmacodynamics data from a phase I trial in hypertriglyceridaemia released by Matinas BioPharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top